Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance.
Date: February 28, 2018
Author: Alex Dale
Excerpt: “Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections caused by the WHO’s priority pathogens, a catalog of 12 bacterial families. The fund is expected to invest $20-40M (€16-33M) per year in around 20 projects in Europe and the US, with the hope of driving at least one new therapy to market.”